Inhibition of long-chain acyl coenzyme A synthetases during fatty acid loading induces lipotoxicity in macrophages.
OBJECTIVE
Obesity is often associated with hypertriglyceridemia and elevated free fatty acids (FFAs), which are independent risk factors for cardiovascular disease and diabetes. Although impairment of cholesterol homeostasis is known to induce toxicity in macrophages, the consequence of altered fatty acid homeostasis is not clear.


RESULTS
Long-chain acyl CoA synthetases (ACSLs) play a critical role in fatty acid homeostasis by channeling fatty acids to diverse metabolic pools. We treated mouse peritoneal macrophages (MPMs) with VLDL or FFAs in the presence of triacsin C, an inhibitor of the 3 ACSL isoforms present in macrophages. Treatment of macrophages with VLDL and triacsin C resulted in reduced TG accumulation but increased intracellular FFA levels, which induced lipotoxicity characterized by apoptosis. Treatment of MPMs with the saturated fatty acid stearic acid in the presence of triacsin C increased intracellular stearic acid and induced apoptosis. Stromal vascular cells collected from high-fat diet-fed mice displayed foam cell morphology and exhibited increased mRNA levels of macrophage markers and ACSL1. Importantly, all of these changes were associated with increased FFA level in AT.


CONCLUSIONS
Inhibition of ACSLs during fatty acid loading results in apoptosis via accumulation of FFAs. Our data have implications in understanding the consequences of dysregulated fatty acid metabolism in macrophages.
Saraswathi
Viswanathan
V
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN 37232-0615, USA.
Hasty
Alyssa H
AH
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002470:Cell Survival; D002478:Cells, Cultured; D015243:Cholesterol, VLDL / Q000378:metabolism / Q000494:pharmacology; D003066:Coenzyme A Ligases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism* / Q000494:pharmacology; D050356:Lipid Metabolism / Q000187:drug effects / Q000502:physiology*; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D012680:Sensitivity and Specificity; D014226:Triazenes / Q000494:pharmacology
D015243:Cholesterol, VLDL; D005230:Fatty Acids, Nonesterified; D014226:Triazenes; C034613:triacsin C; D003066:Coenzyme A Ligases
Atherosclerosis. 2005 Jun;180(2):233-44
15910848
Biochemistry. 2005 Feb 8;44(5):1635-42
15683247
Arterioscler Thromb. 1992 Dec;12(12):1458-66
1450177
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3077-82
12629214
J Biol Chem. 2008 Jan 25;283(4):1773-7
18024425
J Clin Invest. 1982 Jul;70(1):168-78
6282937
Am J Med. 2007 Mar;120(3 Suppl 1):S3-S11
17320520
Curr Opin Lipidol. 2003 Jun;14(3):281-7
12840659
J Lipid Res. 1993 May;34(5):703-17
8509711
J Biol Chem. 2001 Jul 6;276(27):24667-73
11319222
J Clin Invest. 2003 Dec;112(12):1796-808
14679176
Nutr Metab Cardiovasc Dis. 2009 Feb;19(2):146-52
19171470
Diabetes. 2007 Apr;56(4):1143-52
17259370
Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S5-9
11921432
Am J Med. 2007 Feb;120(2 Suppl 1):S3-8; discussion S29-32
17296343
J Lipid Res. 2004 May;45(5):972-80
14967823
J Clin Invest. 2003 Dec;112(12):1821-30
14679177
J Lipid Res. 2004 May;45(5):794-804
14993245
Annu Rev Nutr. 1989;9:253-70
2669873
Arteriosclerosis. 1984 Mar-Apr;4(2):103-14
6704048
Am J Clin Nutr. 2000 Jan;71(1):81-7
10617950
J Lipid Res. 2004 Oct;45(10):1958-61
15292367
J Biol Chem. 2006 Jan 13;281(2):945-50
16263710
Horm Metab Res. 2007 Oct;39(10):722-5
17952833
J Biol Chem. 2007 Nov 30;282(48):35279-92
17916553
Am J Physiol Endocrinol Metab. 2006 Oct;291(4):E737-44
16705061
J Lipid Res. 2006 Jul;47(7):1406-15
16639077
J Biol Chem. 2003 Oct 31;278(44):43008-13
12937175
J Biol Chem. 2000 Aug 4;275(31):23807-13
10791964